AC Immune (ACIU) Stock Rating Upgraded by Zacks Investment Research

AC Immune (NASDAQ:ACIU) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued on Monday.

According to Zacks, “AC Immune SA is a biopharmaceutical company. It develops, discover and design novel, proprietary medicines for prevention, diagnosis and treatment of neurodegenerative diseases. The Company’s pipeline includes Crenezumab, ACI-24, Anti-Tau antibody, Morphomer Tau, Tau-PET imaging agent, Morphomer Abeta and Morphomer alpha-syn which are in clinical trial. AC Immune SA is based in Lausanne, Switzerland. “

Separately, BidaskClub lowered shares of AC Immune from a “strong-buy” rating to a “buy” rating in a research note on Friday, January 19th.

Shares of AC Immune (NASDAQ ACIU) traded down $0.03 during trading on Monday, reaching $12.60. 53,830 shares of the company’s stock were exchanged, compared to its average volume of 49,724. AC Immune has a twelve month low of $6.03 and a twelve month high of $13.91.

AC Immune (NASDAQ:ACIU) last issued its quarterly earnings results on Monday, November 13th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.20) by $0.04. equities research analysts expect that AC Immune will post -0.57 earnings per share for the current fiscal year.

Several hedge funds have recently added to or reduced their stakes in ACIU. Belpointe Asset Management LLC purchased a new stake in shares of AC Immune in the 3rd quarter valued at $571,000. Goldman Sachs Group Inc. purchased a new stake in shares of AC Immune in the 2nd quarter valued at $127,000. Janney Montgomery Scott LLC purchased a new stake in shares of AC Immune in the 3rd quarter valued at $134,000. Finally, Wells Fargo & Company MN purchased a new stake in shares of AC Immune in the 3rd quarter valued at $111,000. 17.12% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: This story was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this story on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this story can be viewed at https://www.americanbankingnews.com/2018/02/05/ac-immune-aciu-stock-rating-upgraded-by-zacks-investment-research.html.

About AC Immune

AC Immune SA is a Switzerland-based company engaged in the medical biotechnology sector. It develops treatments for Alzheimer’s and other neurodegenerative diseases, such as Down syndrome, glaucoma and Parkinson’s, and focuses on producing therapeutic and diagnostic product candidates, using SupraAntigen and Morphomer technology platforms.

Get a free copy of the Zacks research report on AC Immune (ACIU)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for AC Immune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply